Available IPD datapackage for study 'A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat® Inhaler Once Daily in the Evening Over 48 Weeks in Children (6 to 11 Years Old) With Moderate Persistent Asthma'

The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily in the evening) over 48 weeks, compared to placebo, in children (6 to 11 years old) with moderate persistent asthma.

本临床试验的总体目标为，针对6至11岁中度持续性哮喘儿童，评估经Respimat®吸入器给药的噻托溴铵吸入溶液（晚间每日一次，剂量分别为2.5微克与5微克）在为期48周的疗程中的有效性与安全性，并以安慰剂作为对照。